Legal

Terms of service

Version 1.0Effective 17 August 2026Last reviewed 17 August 2026

These terms are published in draft and have not yet been reviewed by a qualified lawyer. They describe how the service actually works, which is the part we can state accurately. Where a hospital has a signed service agreement with us, that agreement governs and these terms fill only the gaps. Section 13 lists what is still open.

1. Who these terms bind

They apply to hospitals, cancer centres, clinicians and individuals who order testing from us or use the portal at portal.oncoprint.ai. Using the portal, or sending us a specimen, means accepting them.

Where a signed service agreement exists, it takes precedence over anything here that conflicts with it.

2. What we provide

Laboratory testing — comprehensive genomic profiling, ctDNA and residual disease monitoring, pharmacogenomics, immunohistochemistry, in-situ hybridisation and whole-slide imaging — and a report issued under the signature of a qualified pathologist.

We provide the result and its interpretation in the context given to us. We are not the treating clinician.

3. What we do not provide

Stated bluntly because the distinction matters clinically:

  • We do not practise medicine. A report informs a clinical decision; it does not make one. Treatment remains the responsibility of the treating clinician, who is expected to read the result in the context of the patient in front of them.
  • A report is not a diagnosis on its own, and is not valid detached from its limitations, its methodology and its stated scope.
  • We do not provide emergency services. Nothing here is a route for a decision that must be made today. Telephone the laboratory.

4. Ordering and consent

By placing an order you confirm that:

  • You are entitled to order the test and to give us the clinical information accompanying it.
  • Valid, informed consent has been obtained from the patient — including, where genetic testing may reveal heritable findings, consent covering that possibility and the implications for relatives. Obtaining consent is the ordering clinician's responsibility, not ours.
  • The information you supply is accurate. Identification, specimen site and clinical context all affect interpretation, and a result interpreted against wrong context can be wrong while being technically correct.

5. Specimens

  • Specimens must be collected, labelled, preserved and transported to our published requirements. Ask us before sending anything unusual.
  • We may decline or cancel a specimen that is inadequate, mislabelled, degraded, or has insufficient tumour content. We will tell you why rather than reporting a result we do not trust.
  • Residual material is retained per our retention schedule and then destroyed. Repeat testing may be impossible once it is gone.
  • Risk in a specimen passes to us on receipt at the laboratory.

6. Turnaround

Published turnaround times are measured from receipt of an adequate specimen with a complete order, and are targets rather than guarantees. Repeat testing, poor sample quality, reflex assays and tumour board review extend them.

If a case will miss its commitment we tell you before the date, not after.

7. Reports and amendments

  • A report is issued when a pathologist signs it. Only a pathologist may do so.
  • A signed report is immutable. A correction is issued as an amendment that names what changed and why; the original is never overwritten, because a clinical decision may already have been taken on it.
  • You must not alter a report, or reproduce part of one in a way that separates a result from its limitations.
  • Reports are released only to the ordering clinician, their organisation, and others entitled to receive them.

8. Limitations of testing

Every assay has limits, and a report that hid them would be misleading:

  • A negative result means not detected by this assay at its limit of detection — not absent.
  • Panels cover defined regions. Variants outside the panel, and classes of variant a method cannot see, are not excluded by a negative result.
  • Variant classification reflects evidence available at the date of the report and may change. Reinterpretation is available on request; we do not undertake to reissue reports automatically as evidence moves.
  • Pharmacogenomic results carry population limitations. Where an interpretation is limited for a patient's ancestry, the report says so in full sentences rather than as a flag, and an uncharacterised allele yields no activity score rather than being scored as normal.
  • Some assays are validated for specific indications only. Where a result falls outside our accredited scope, the report says so and carries no accreditation mark.

9. Using the portal

  • Accounts are issued to named individuals and must not be shared. Signing in ends any other live session for the account, and the count is shown — if you see it and did not expect it, your password is shared or compromised.
  • Tell us immediately if you believe an account has been compromised.
  • You may access only the records you are entitled to. Attempting to reach another organisation's data is a breach of these terms independently of whether it succeeds. It will not succeed: isolation is enforced at the database, and every attempt is logged.
  • An organisation's administrator is responsible for removing accounts for people who have left.
  • Do not scrape, load-test or attempt to bypass access controls without our written agreement.
  • Availability is not guaranteed. Maintenance is notified where practicable.

10. Fees and billing

  • Fees are those quoted or in the agreed schedule. Individuals are quoted before anything is run.
  • Claim codes are derived from the assays actually performed, not from what was ordered — an ordered test that could not be run is not billed as if it had been.
  • BHYT coverage depends on assay and indication and is confirmed before testing where it applies. Where a claim is refused, the balance falls to the party who ordered.
  • Invoices are payable per the agreed terms; disputes must be raised within 30 days of invoice.

11. Intellectual property

The platform, its software, the report templates and the OncoPrint name and mark remain ours. Nothing here transfers them.

You keep your rights in the clinical information you supply. The report issued for a patient may be used freely for that patient's care.

12. Liability

Nothing in these terms limits liability that cannot lawfully be limited — including for death or personal injury caused by negligence, or for fraud.

Subject to that, and to the sections above on what we do and do not provide:

  • We are not liable for clinical decisions taken on a report, which remain the treating clinician's.
  • We are not liable for consequences of inaccurate information supplied with an order, or of a specimen that did not meet requirements.
  • We are not liable for indirect or consequential loss, or for loss of profit, revenue or opportunity.
  • Our aggregate liability for any claim is limited to the fees paid for the testing giving rise to it.

If a result appears clinically inconsistent, contact us before acting on it. We would far rather repeat a test than have a questionable result used.

13. What is still open

Listed so nobody relies on something unfinished:

  • Legal review, and alignment with the standard hospital service agreement.
  • The registered legal entity, address and business registration number.
  • The published specimen requirements and retention schedule these terms refer to.
  • Governing law and dispute resolution, including whether disputes go to arbitration.
  • A Vietnamese translation. Where the two differ, the Vietnamese text will govern for customers in Vietnam.

14. General

  • We may change these terms; the effective date above moves when we do, and material changes are notified to organisations holding accounts.
  • If a provision is unenforceable, the rest stands.
  • Failure to enforce a term is not a waiver of it.
  • Accounts may be suspended for breach of section 9, or where continued access would put patient data at risk.

See also the privacy notice, which covers what we do with personal and health data.